Charles Schwab
ALXO icon

Charles Schwab’s ALX Oncology ALXO Stock Holding History

Charles Schwab’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-133,433
Closed -$55.4K – 3461
2025
Q2 		$55.4K Sell
133,433
-77,618
-37% -$39.2K ﹤0.01% 3445
2025
Q1 		$131K Sell
211,051
-5,656
-3% -$6.79K ﹤0.01% 3300
2024
Q4 		$362K Sell
216,707
-8,595
-4% -$13.2K ﹤0.01% 3232
2024
Q3 		$410K Sell
225,302
-10,718
-5% -$39.8K ﹤0.01% 3213
2024
Q2 		$1.42M Buy
236,020
+26,261
+13% +$323K ﹤0.01% 2807
2024
Q1 		$2.34M Buy
209,759
+1,595
+0.8% +$22.4K ﹤0.01% 2545
2023
Q4 		$3.1M Buy
208,164
+67,430
+48% +$640K ﹤0.01% 2499
2023
Q3 		$676K Sell
140,734
-24,817
-15% -$135K ﹤0.01% 2934
2023
Q2 		$1.24M Buy
165,551
+15,079
+10% +$98.7K ﹤0.01% 2697
2023
Q1 		$680K Sell
150,472
-9,513
-6% -$72.1K ﹤0.01% 2853
2022
Q4 		$1.8M Buy
159,985
+8,483
+6% +$95.3K ﹤0.01% 2601
2022
Q3 		$1.45M Sell
151,502
-211
-0.1% -$2.46K ﹤0.01% 2680
2022
Q2 		$1.23M Buy
151,713
+18,234
+14% +$199K ﹤0.01% 2719
2022
Q1 		$2.26M Sell
133,479
-6,403
-5% -$109K ﹤0.01% 2606
2021
Q4 		$3.01M Buy
139,882
+1,176
+0.8% +$50.7K ﹤0.01% 2570
2021
Q3 		$10.2M Buy
138,706
+46,002
+50% +$3.07M ﹤0.01% 1995
2021
Q2 		$5.07M Buy
92,704
+1,734
+2% +$104K ﹤0.01% 2349
2021
Q1 		$6.71M Buy
90,970
+18,939
+26% +$1.49M ﹤0.01% 2156
2020
Q4 		$6.21M Buy
72,031
+14,107
+24% +$849K ﹤0.01% 2113
2020
Q3 		$2.19M Buy
+57,924
New +$2.28M ﹤0.01% 2464

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Charles Schwab's ALXO Position: Q3 2025 in Review

Charles Schwab sold out of ALX Oncology (ALXO) in Q3 2025, closing a stake of 133,433 shares — an estimated $55.4K sold.

Charles Schwab first reported a position in ALXO in Q3 2020 and held it in 20 quarters. The position peaked at $10.2M in Q3 2021. 61 funds tracked by Wall St. Rank hold ALXO as of Q3 2025.

  • Charles Schwab reported no remaining ALX Oncology position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 133,433 ALX Oncology shares in Q3 2025, an estimated $55.4K.
  • Charles Schwab first reported a position in ALX Oncology in Q3 2020 and held it in 20 quarters.
  • Charles Schwab's ALX Oncology position peaked at $10.2M in Q3 2021.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.